The Centers for Medicare and Medicaid Services will work to ensure that new generics and biosimilars that could disrupt or delay price negotiation for brands are not encumbered by distribution or sales limits dictated by the reference product manufacturer, the agency says in its initial guidance for the program.
Released on 15 March, the guidance covers the Medicare negotiation process for prices that go into effect in 2026, the...







